{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:00:58Z","timestamp":1784772058835,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adalimumab is a tumor necrosis factor-\u03b1 inhibitor, which is associated with an increased risk of tuberculosis. However, evidence regarding tuberculosis development in patients with pyoderma gangrenosum is limited, and simultaneous involvement in lungs, pleura, and pericardium is rare. This report describes a case of pulmonary tuberculosis and tuberculous pleuropericarditis associated with adalimumab administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      The patient was a 59-year-old Filipino female. She began receiving adalimumab to treat pyoderma gangrenosum at the dermatology department of our hospital. The serum interferon-gamma release assay using QuantiFERON test, measured prior to administration, was negative. After five times of administration, she presented with fever, cough, and dyspnea. A chest computed tomography scan showed multiple small nodular shadows in the lung fields, right pleural effusion, and pericardial effusion. The administration of antibiotics and diuretics was ineffective. The QuantiFERON test was repeated, and was positive. The rapid sputum test for tuberculosis antigen was positive, and\n                      <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                      was subsequently cultured 23\u00a0days later. Thus, she was diagnosed with pulmonary tuberculosis. Standard treatment with a combination of four antituberculous drugs was started, but drug susceptibility testing revealed resistance to isoniazid, so isoniazid was changed to levofloxacin. After treatment, multiple small nodular shadows in the lung fields disappeared, and the pleural and pericardial effusions completely resolved. Thus, we clinically diagnosed pulmonary tuberculosis with combined tuberculous pleuropericarditis. To the best of our knowledge, there have been no reports of pulmonary tuberculosis and tuberculous pleuropericarditis following adalimumab administration.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights the importance of considering both pulmonary and extrapulmonary tuberculosis as potential complications of adalimumab, even in patients with initially negative interferon-gamma release assay results. Repeat testing may be crucial for early detection, especially in high-risk individuals from endemic areas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-06129-1","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T04:43:00Z","timestamp":1779856980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pulmonary tuberculosis and tuberculous pleuropericarditis in a patient with pyoderma gangrenosum treated with adalimumab: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Kei","family":"Kanata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoma","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Ichijo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"3","key":"6129_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","author":"M Pai","year":"2008","unstructured":"Pai M, Zwerling A, Menzies D. Systematic review: T-Cell\u2013based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177\u201384.","journal-title":"Ann Intern Med"},{"key":"6129_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/187152809787582543","volume":"8","author":"A Mootoo","year":"2009","unstructured":"Mootoo A, Stylianou E, Arias MA, Reljic R. TNF-\u03b1 in tuberculosis: a cytokine with a split personality. Inflamm Allergy Drug Targets. 2009;8:53\u201362.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"6129_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.smim.2014.04.003","volume":"26","author":"A Dorhoi","year":"2014","unstructured":"Dorhoi A, Kaufmann SHE. Tumor necrosis factor alpha in mycobacterial infection. Semin Immunol. 2014;26:203\u20139.","journal-title":"Semin Immunol"},{"key":"6129_CR4","doi-asserted-by":"publisher","DOI":"10.4110\/in.2024.24.e4","volume":"24","author":"JM Yuk","year":"2024","unstructured":"Yuk JM, Kim JK, Kim IS, Jo EK. TNF in human tuberculosis: a double-edged sword. Immune Netw. 2024;24: e4.","journal-title":"Immune Netw"},{"key":"6129_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","volume":"8","author":"RS Wallis","year":"2008","unstructured":"Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601\u201311.","journal-title":"Lancet Infect Dis"},{"key":"6129_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2010.04146.x","volume":"161","author":"J Harris","year":"2010","unstructured":"Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol. 2010;161:1\u20139.","journal-title":"Clin Exp Immunol"},{"key":"6129_CR7","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/ncprheum0336","volume":"2","author":"KL Winthrop","year":"2006","unstructured":"Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602\u201310.","journal-title":"Nat Clin Pract Rheumatol"},{"key":"6129_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.980868","volume":"12","author":"R Ha","year":"2022","unstructured":"Ha R, Keynan Y, Rueda ZV. Increased susceptibility to pneumonia due to tumour necrosis factor inhibition and prospective immune system rescue via immunotherapy. Front Cell Infect Microbiol. 2022;12: 980868.","journal-title":"Front Cell Infect Microbiol"},{"key":"6129_CR9","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1086\/593174","volume":"198","author":"J Harris","year":"2008","unstructured":"Harris J, Hope JC, Keane J. Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. J Infect Dis. 2008;198:1842\u201350.","journal-title":"J Infect Dis"},{"issue":"5","key":"6129_CR10","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s10165-012-0727-5","volume":"23","author":"N Yasuo","year":"2013","unstructured":"Yasuo N, Hirofumi S, Keishi F, Satoru I, Haruhito S, Kazuhiko Y. Tuberculous pleurisy diagnosed by medical thoracoscopy in an adalimumab-treated rheumatoid arthritis patient after treatment of latent tuberculosis infection. Mod Rheumatol. 2013;23(5):1013\u20137.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"6129_CR11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0123-9392(10)70092-8","volume":"14","author":"H Patricia","year":"2010","unstructured":"Patricia H, Jorge E, Martin GJ. Pleural tuberculosis associated with adalimumab in a patient with rheumatoid arthritis. Infectio. 2010;14(1):47\u201354.","journal-title":"Infectio"},{"key":"6129_CR12","doi-asserted-by":"publisher","first-page":"S1197","DOI":"10.14309\/01.ajg.0000711104.69535.9c","volume":"115","author":"M Mironova","year":"2020","unstructured":"Mironova M, Gutierrez P, Irina Y, Anandakrishnan R, Balani A. Tuberculous pericardial tamponade in the patient with crohn\u2019s disease treated with adalimumab. Am J Gastroenterol. 2020;115:S1197\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"6129_CR13","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1080\/00365540701877320","volume":"40","author":"A Jose","year":"2008","unstructured":"Jose A, Marcos A, Clara H, Margarita B, Laura M, Ramon C. Tuberculous peritonitis after treatment with adalimumab. Scand J Infect Dis. 2008;40(8):677\u20138.","journal-title":"Scand J Infect Dis"},{"issue":"Suppl 1","key":"6129_CR14","first-page":"S97","volume":"10","author":"K Melissa","year":"2024","unstructured":"Melissa K, Fatme G, Elias S. Adalimumab-induced isolated peritoneal tuberculosis. Int J Recent Surg Med Sci. 2024;10(Suppl 1):S97.","journal-title":"Int J Recent Surg Med Sci"},{"issue":"4","key":"6129_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/RC9.0000000000000350","volume":"138","author":"K Yigzaw","year":"2026","unstructured":"Yigzaw K, Shibesh M, Asfaw BA, Zewudu AA, Mengistie BT, Tegegne BA. Uncommon cause of airway obstruction and hypovolemic shock: pharyngeal leech infestation in a rural Ethiopian child. Int J Surg Case Rep. 2026;138(4):1467\u201370.","journal-title":"Int J Surg Case Rep"},{"key":"6129_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2025.107880","volume":"155","author":"T Alonzi","year":"2025","unstructured":"Alonzi T, Petruccioli E, Aiello A, Repele F, Goletti D. Diagnostic tests for tuberculosis infection and predictive indicators of disease progression: utilizing host and pathogen biomarkers to enhance the tuberculosis elimination strategies. Int J Infect Dis. 2025;155: 107880.","journal-title":"Int J Infect Dis"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06129-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06129-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06129-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:08:46Z","timestamp":1784768926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06129-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6129"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06129-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"23 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this case report. The authors declare that appropriate written informed consent was obtained for the publication of this manuscript and accompanying images.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent form is available for review by the Editor-in-Chief of the journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"420"}}